Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
Status:
NOT_YET_RECRUITING
Trial end date:
2026-07-15
Target enrollment:
Participant gender:
Summary
Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).